Oncopharmpod
Axi-Cel and 5-FU Label Changes
- Author: Vários
- Narrator: Vários
- Publisher: Podcast
- Duration: 0:12:34
- More information
Informações:
Synopsis
We have FDA changes to the labels of Axi-Cel (to allow for its use in primary CNS lymphoma) and 5-flourouracil (pre-treatment DPYD testing). Also, pembrolizumab nets another approval, this time in conjunction with paclitaxel for platinum-resistant ovarian cancer (limited to PD-L1 CPS of 1% of greater)
